<DOC>
	<DOC>NCT01363934</DOC>
	<brief_summary>This is a Dose-Block Randomized, Double-blind Placebo controlled, Open-label Active controlled, Dose-escalation Study to investigate the safety, tolerability, and Pharmacokinetics/Pharmacodynamics of GC1113 after Single Intravenous/Subcutaneous Administration in Healthy Male Subjects.</brief_summary>
	<brief_title>To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin</brief_title>
	<detailed_description />
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Written informed consent Adult male subjects between 20 to 55 years of age 60kg ≤ weight ≤ 90kg, 19 ≤ BMI ≤ 27 12 g/dL ≤ Hemoglobin ≤ 16 g/dL within the 28 days prior to investigational product (IP)injection WBC ≥ 3.0Ⅹ10^9/L, platelet ≥ 140Ⅹ10^9/L within the 28 days prior to IP injection Allergic to IP ingredients History of uncontrolled liver, kidney, respiratory, endocrine, neurology, immunology, hematology, mental symptom, circulatory and malignancy disease Prior exposure to EPO, darbepoetin, other EPO, immunoglobulin, IV iron supplementation History of hypersensitivity reaction to EPO, darbepoetin, excipient of IP or hyperergia to iron supplementation Epilepsy within the 6 months prior to IP injection Positivity for HIV antibody, HBsAg, HCV antibody test Spleen length &gt; 16㎝</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Erythropoietin</keyword>
	<keyword>EPO-hFC</keyword>
</DOC>